@entity3524 is more effective than is @entity869 - XXXX in cirrhotics with severe @entity281 .

@entity1 @entity8 @entity2890 @entity2262 @entity2348 @entity3524 @entity281 @entity869 @entity298
We compared the effectiveness and incidence of nephrotoxicity of @entity869 - @entity2890 and @entity3524 in 73 cirrhotics who had severe @entity2348 . Most of these @entity1 had @entity298 . @entity1 were randomly allocated into two groups. Group I included 36 @entity1 treated with @entity869 - @entity2890 and Group II comprised 37 @entity1 treated with @entity3524 . @entity1 from both groups were similar with respect to clinical data, standard liver and renal function tests, types of @entity281 and isolated organisms. Ninety-two per cent of bacteria isolated in Group I and 98% of those isolated in Group II were susceptible in vitro to @entity869 - @entity2890 and to @entity3524 , respectively. @entity869 - @entity2890 cured the @entity281 in 56% of Group I @entity1 , and @entity3524 in 85% of Group II @entity1 (p less than 0.02). Five @entity1 treated with @entity869 - @entity2890 , and none treated with @entity3524 developed superinfections (p = 0.024). Nephrotoxicity ( @entity8 associated with an increase of urinary @entity2262 to over 2,000 micrograms per liter) occurred in two @entity1 in Group I and none in Group II. These results suggest that broad-spectrum cephalosporins should be considered as first choice antibiotics in cirrhotic @entity1 with severe @entity281 .
